The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders

English version

Autoři: Riswandy Wasir ^aff001; Sylvi Irawati ^aff003; Amr Makady ^aff006; Maarten Postma ^aff003; Wim Goettsch ^aff006; Talitha Feenstra ^aff001; Erik Buskens ^aff001
Působiště autorů: Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands ^aff001; Sekolah Tinggi Ilmu Farmasi Makassar, Makassar, Indonesia ^aff002; Groningen Research Institute of Pharmacy, Faculty of Science and Engineering, University of Groningen, Groningen, the Netherlands ^aff003; Center for Medicines Information and Pharmaceutical Care, Faculty of Pharmacy, Universitas Surabaya, Surabaya, Indonesia ^aff004; Department of Clinical and Community Pharmacy, Faculty of Pharmacy, Universitas Surabaya, Surabaya, Indonesia ^aff005; National Health Care Institute, Diemen, the Netherlands ^aff006; Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, the Netherlands ^aff007; Department of Health Sciences, University of Groningen, Groningen, The Netherlands ^aff008; Department of Economics, Econometrics & Finance, Faculty of Economics & Business, University of Groningen, Groningen, the Netherlands ^aff009; Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia ^aff010; Dutch National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands ^aff011; Department of Operations, Faculty of Economics & Business, University of Groningen, Groningen, the Netherlands ^aff012
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pone.0225626

Souhrn

Objectives

This study aimed to identify the barriers and facilitators to improve the use of health technology assessment (HTA) for the selection of medicines listed in the e-Catalogue and the national formulary in Indonesia.

Methods

Semi-structured interviews were conducted to collect qualitative data. Purposive sampling was used to recruit the stakeholders consisting of policymakers, a pharmaceutical industry representative, healthcare providers, and patients. The data were analyzed using directed content analysis and following the COnsolidated criteria for REporting Qualitative studies (COREQ).

Results

The twenty-five participants interviewed agreed with the use of HTA for supporting the e-Catalogue and the national formulary and perceived the advantages of HTA implementation outweighed the disadvantages. Barriers mentioned were a lack of capability of local human resources, financial incentives, a clear framework and insufficient data. Strategies suggested to overcome the barriers were establishing (inter)national networks to build up capacity, setting up departments of HTA in several universities in Indonesia, and introducing a clear HTA framework. Facilitators mentioned were the ambition to achieve universal health coverage, the presence of legal frameworks to implement HTA in the e-Catalogue and the national formulary, and the demands for appropriate medicine policies.

Conclusions

Several barriers are currently hampering broad implementation of HTA in medicine pricing and reimbursement policy in Indonesia. Solutions to these issues appear feasible and important facilitators exist.

Klíčová slova:

Health care providers – Physicians – Allied health care professionals – Health economics – Health care policy – Pharmacists – Indonesia – Health care sector

Zdroje

1. Sachs JD. From millennium development goals to sustainable development goals. Lancet. 2012;379(9832):2206–2211. doi: 10.1016/S0140-6736(12)60685-0 22682467

2. Kieny MP, Bekedam H, Dovlo D, Fitzgerald J, Habicht J, Harrison G, et al. Strengthening health systems for universal health coverage and sustainable development. Bull World Health Organ. 2017;95(7):537–539. doi: 10.2471/BLT.16.187476 28670019

3. World Health Organization. Tracking universal health coverage: First global monitoring report. World Health Organization; 2015.

4. Khan JA, Ahmed S, Evans TG. Catastrophic healthcare expenditure and poverty related to out-of-pocket payments for healthcare in bangladesh—an estimation of financial risk protection of universal health coverage. Health Policy Plan. 2017;32(8):1102–1110. doi: 10.1093/heapol/czx048 28575415

5. Bigdeli M, Laing R, Tomson G. Medicines and universal health coverage: Challenges and opportunities. 2015. doi: 10.1186/s40545-015-0028-4 25825675

6. Yoongthong W, Hu S, Whitty JA, Wibulpolprasert S, Sukantho K, Thienthawee W, et al. National drug policies to local formulary decisions in thailand, china, and australia: Drug listing changes and opportunities. Value Health. 2012;15(1 Suppl):S126–31.

7. Chalkidou K, Marten R, Cutler D, Culyer T, Smith R, Teerawattananon Y, et al. Health technology assessment in universal health coverage. Lancet. 2013;382(9910):e48–9. doi: 10.1016/S0140-6736(13)62559-3 24360390

8. World Health Organization. Health technology assessment, HTA, WHO definition (EB 134/30). Updated Access on January 5, 2019.

9. Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: Results of a systematic review and expert consultation across eight european countries. The European Journal of Health Economics. 2018;19(1):123–152. doi: 10.1007/s10198-017-0871-0 28303438

10. Republik Indonesia Undang-undang republik indonesia nomor 24 tahun 2011 tentang badan penyelenggara jaminan sosial.; 2011.

11. Mundiharno TH. Peta jalan menuju jaminan kesehatan nasional 2012–2019.; 2012.

12. Menteri Kesehatan Republik Indonesia. Peraturan menteri kesehatan republik indonesia nomor 28 tahun 2014 tentang pedoman pelaksanaan program jaminan kesehatan nasional.; 2014.

13. Kemetrian Kesehatan Republik Indonesia. Pedoman penerapan formularium nasional. 2015.

14. Menteri Kesehatan Republik Indonesia. Peraturan menteri kesehatan republik indonesia nomor 63 tahun 2014 tentang pengadaan obat berdasarkan katalog elektronik (E-catalogue).; 2014.

15. Kementrian Kesehatan R. Pedoman penerapan kajian farmakoekonomi. Direktorat Jendral Bina Kefarmasian dan Alat Kesehatan, Jakarta. 2013.

16. Menteri Kesehatan Republik Indonesia. Keputusan menteri kesehatan republik indonesia nomor 171/ menkes/ SK/ IV/ 2014 tentang komite penilaian teknologi kesehatan. 2014.

17. Menteri Kesehatan Republik Indonesia. Keputusan menteri kesehatan RI no. HK.02.02/menkes/422/2016 tentang komite penilaian teknologi kesehatan. 2016.

18. Wasir R, Irawati S, Makady A, Postma M, Goettsch W, Buskens E, et al. Use of medicine pricing and reimbursement policies for universal health coverage in indonesia. PloS one. 2019;14(2):e0212328. doi: 10.1371/journal.pone.0212328 30779809

19. World Health Organization. Global health expenditure database. access on October 29, 2018.

20. Hidayat B, Mundiharno, Nemec J, Rabovskaja V, Rozanna C, Spatz J. Out-of-pocket payments in the national health insurance of indonesia. 2015.

21. Dirjen Binfar dan Alkes Kemenkes RI. Implementasi formularium nasional dalam pelaksanaan jaminan kesehatan nasional. 2015.

22. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups. International journal for quality in health care. 2007;19(6):349–357. doi: 10.1093/intqhc/mzm042 17872937

23. Hsieh H, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–1288. doi: 10.1177/1049732305276687 16204405

24. World Health Organization. WHO guideline on country pharmaceutical pricing policies. World Health Organization; 2015.

25. Babigumira JB, Jenny AM, Bartlein R, Stergachis A, Garrison LP Jr. Health technology assessment in low‐and middle‐income countries: A landscape assessment. Journal of Pharmaceutical Health Services Research. 2016;7(1):37–42.

26. Jaafar S, Noh Kamaliah Mohd, Muttalib Khairiyah Abdul, Othman NH, Healy J, Maskon K, et al. Malaysia health system review. 2013.

27. Babar Z. Pharmaceutical policy in countries with developing healthcare systems. Springer International Publishing AG; 2017.

28. Nguyen TA, Vitry A, Roughead EE. Pharmaceutical policy in vietnam. In: Pharmaceutical policy in countries with developing healthcare systems. Springer; 2017:75–94.

29. Teerawattananon Y, Tantivess S, Yothasamut J, Kingkaew P, Chaisiri K. Historical development of health technology assessment in thailand. Int J Technol Assess Health Care. 2009;25(S1):241–252.

30. Presiden Republik Indonesia. Peraturan presiden republik indonesia nomor 12 tahun 2013 tentang jaminan kesehatan.; 2013.

31. Kaló Z, Gheorghe A, Huic M, Csanádi M, Kristensen FB. HTA implementation roadmap in central and eastern european countries. Health Econ. 2016;25(S1):179–192.